Pancreatic Cancer: Discovery Could Revolutionize Treatment

A novel targeted therapy combined with chemotherapy has demonstrated significant tumor reduction in patients with advanced pancreatic cancer, offering a potential major advancement in treatment. Preliminary results from a U.S. clinical study, presented at the European Society of Digestive Oncology 2026 congress in Munich, indicated promising outcomes with no unexpected side effects.

Pancreatic cancer remains one of the most aggressive and difficult cancers to treat, often diagnosed at a late stage due to subtle early symptoms. The five-year survival rate is typically below 3%. Researchers at the Dana-Farber Cancer Institute in Boston noted that approximately 90% of patients have a KRAS gene mutation, with KRAS G12D being a significant factor. This mutation, long considered hard to target, is now the focus of new therapeutic strategies.

The experimental drug zoldonrasib directly targets the mutated protein driving tumor growth, distinguishing it from chemotherapy, which affects all rapidly dividing cells. The study involved 81 patients with metastatic pancreatic cancer who had not received prior treatment. They were divided into two groups: one received zoldonrasib with a modified FOLFIRINOX protocol, and the other received gemcitabine and nab-paclitaxel.

Results showed an 82% tumor response rate in the zoldonrasib group, compared to 61% in the control group. Disease control was achieved in 96% of patients on FOLFIRINOX and 90% in the other group. Blood markers related to cancer also significantly decreased, with 47% of patients in the first group and 71% in the second showing a complete disappearance of cancer signs in their blood. Importantly, the addition of zoldonrasib did not introduce new side effects beyond those typically associated with chemotherapy, such as nausea, diarrhea, and fatigue. Researchers believe targeting the KRAS G12D mutation is one of the most promising avenues in pancreatic cancer research, potentially leading to more effective and better-tolerated combination therapies.